Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 19, 2025Open Access

PK/PD study of ceftazidime/avibactam in patients with severe intra-abdominal infections treated by continuous veno–venous hemofiltration

View Full Paper
Ask AI
Bookmark
Share

Authors

STSai TianYCYong ChenMQMingjie Qiu

Discussion

Loading...

Member takes

Overview

Study shows the impact of continuous veno-venous hemofiltration on ceftazidime and avibactam clearance in severe intra-abdominal infections, indicating the need for individualized dosing.

Key Points

  • Ceftazidime and avibactam clearance increased significantly during continuous veno-venous hemofiltration.
  • Monte Carlo simulations indicated that 3000 mg + 750 mg of ceftazidime/avibactam achieved optimal target attainment under specific conditions.
  • Patients with severe intra-abdominal infections may require individualized dosing based on pharmacokinetics.
  • This study emphasizes the importance of adjusting dosing regimens for effective treatment in special circumstances.

Cite This Study

Tian et al. (2025) studied this question.

synapsesocial.com/papers/68af33e9cf1dd9ea359e9317https://doi.org/10.21203/rs.3.rs-7319086/v1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ceftazidime–Avibactam Pharmacokinetic Comparative In Vivo/In Vitro Study in a Critically Ill Children Under High‐Volume Continuous Venovenous Hemodiafiltration2025
  2. 2Model-informed individualized administration of ceftazidime–avibactam in critically ill patients: population pharmacokinetics studies and a parametric time-to-event analysis2025
  3. 3Continuous infusion versus intermittent dosing of ceftazidime/avibactam in critically ill patients with Klebsiella pneumoniae OXA-48 or Pseudomonas aeruginosa infections: a single-center randomized open-label trial (ZAVICONT). Rationale and design2025
  4. 4Pharmacokinetics/Pharmacodynamics and Therapeutic Drug Monitoring of Ceftazidime/Avibactam in Patients With Gram‐Negative Bacterial Infections2025
  5. 5Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Organisms: A Prospective, Observational, Single-Center Study2025